Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 6/20 | 0.34 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1916141 | 0.87 | LMNA (0.56) | LMNAPLGPLATF2CYP2D6 | |
| Hydrochloric Acid SCHEMBL15158196 | 0.85 | LMNA (0.54) | LMNAPLGPLATF2CYP2D6 | |
| Hydrochloric Acid SCHEMBL9231250 | 0.85 | LMNA (0.54) | LMNAPLGPLATF2CYP2D6 | |
| SCHEMBL14416501 | 0.80 | HPGD (0.44) | LMNAKDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL4186141 | 0.80 | KDM5A (0.45) | LMNAPLGCYP2D6KDM5AKDM7A | |
| SCHEMBL23495089 | 0.79 | LMNA (0.44) | LMNAKDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL8920891 | 0.79 | KDM5A (0.47) | LMNAKDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL301024 | 0.79 | — | — | |
| SCHEMBL672141 | 0.79 | KDM5A (0.47) | LMNAKDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL23495097 | 0.79 | ALOX5 (0.39) | LMNAPLGPLATKDM5AKDM7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130090385-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-11 | — | — | US | disclosed |
| US-8357721-B2 | Therapy for diabetic retinopathy | MERCK PATENT GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| EP-1881960-B1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-20080182906-A1 | Novel Specific Caspase-10 Inhibitors | MERCK PATENT GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
| EP-1881960-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | Merck Patent GmbH (DE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006114190-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182906-A1 | Novel Specific Caspase-10 Inhibitors | CASP10, CASP1, CASP2 | LMNA 738/4885PLG 370/4885PLAT 1099/4885 |
| US-20130090385-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | CASP10, CASP1, CASP2 | LMNA 738/4885PLG 370/4885PLAT 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.